For example, the oncogenic forms of KRAS-mutant desensitised cells to ferroptosis through NRF2-mediated FSP1 upregulation8, whereas p53, the tumour suppressor, promotes ferroptosis by both transcriptionally repressing SLC7A11 and releasing the lipoxygenase activity of ALOX129. Here, TP53 is linked to neoplasm.